Palatin Technologies Inc. (NYSE MKT:PTN) Q4 2020 Earnings Conference Call - Final Transcript
Sep 28, 2020 • 11:00 am ET
strong pipeline of novel clinical drug candidates, and we will remain focused on their advancement. Based on the research work completed in the past year, we are positioned to start clinical studies in COVID-19. Patients of ulcerative colitis and retinal diseases in 2021.
In closing, I would like to thank the Palatin team and all our development partners for their rapid adjustment to a new working environment and their continued dedication to the advancement of Vyleesi, commercial activities in our novel drug candidates.
Thank you, and we'll now open the call to questions.